title: Mizoribine reduces urinary protein excretion in rats given puromycin aminonucleoside.
abstract: Mizoribine (MZR), a purine nucleoside antibiotic, is an effective immunosuppressive agent that prevents rejection reactions after kidney transplantation in humans. The present study was performed to examine the effect of MZR on nephrosis produced in rats given puromycin aminonucleoside (PAN). Urinary protein excretion in rats injected with PAN and MZR (PAN + MZR rats) was shown to be reduced significantly in comparison with rats given only PAN (PAN rats). Although mild hypoproteinemia persisted during the experimental period in PAN + MZR rats, no loss of body weight or state of malnutrition was observed. The reduction of serum IgG and C3 was reversed by administration of MZR. Polyethyleinamine (PEI) staining of renal sections showed increased numbers of anionic sites in PAN + MZR rats in comparison with PAN rats, suggesting that MZR improved the permselectivity of the glomerular basement membrane (GBM). Moreover, the production of thromboxane B2 (TxB2) was significantly inhibited in PAN + MZR rats compared with PAN rats. No serious adverse effects of MZR were observed after a large dose of the agent. It is possible that restoration of the charge barrier of the GBM damaged by PAN, or reduction of TxB2 production by the glomeruli may underlie the reduction of protein excretion induced by administration of MZR.
authors.affiliation: Second Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shibasaki
authors.forename: H
authors.initials: H
authors.lastname: Matsuda
authors.forename: H
authors.initials: H
authors.lastname: Gomi
authors.forename: M
authors.initials: M
authors.lastname: Usui
authors.forename: F
authors.initials: F
authors.lastname: Ishimoto
authors.forename: O
authors.initials: O
authors.lastname: Sakai
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D009401:Nephrosis / Q000139:chemically induced / Q000188:drug therapy; D009402:Nephrosis, Lipoid / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology; D011692:Puromycin Aminonucleoside / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D012263:Ribonucleosides / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000096:biosynthesis*
chemical_list: D000903:Antibiotics, Antineoplastic; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D013929:Thromboxane B2; D011692:Puromycin Aminonucleoside